Why Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 5.24%
As of Friday, August 21, Taysha Gene Therapies, Inc.’s TSHA share price has surged by 5.24%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Commentary & Analysis
Why Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Down 5.24%
As of Wednesday, August 12, Taysha Gene Therapies, Inc.’s TSHA share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 5.30%
As of Monday, July 27, Taysha Gene Therapies, Inc.’s TSHA share price has surged by 5.30%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 5.02%
As of Tuesday, July 14, Taysha Gene Therapies, Inc.’s TSHA share price has surged by 5.02%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Down 5.36%
As of Monday, July 13, Taysha Gene Therapies, Inc.’s TSHA share price has dipped by 5.36%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | TSHA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,990.8 | $286.3 | 53% |
|
| Shares Out (Mil) | 369.0 | 54.2 | 85% |
|
| Institutional Ownership | 88.3% | 92.8% | 56% |
|
| Float (Mil) | 232.6 | 39.7 | 76% |
|
| Beta | 1.19 | 0.94 | 71% |
|
| Avg Daily Volume (000s) | 2,829 | 534 | 87% |
|
| Price Change (52-week) |
115.1% | 58.7% | 93% |
|
| Growth | TSHA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (12.7%) | (10.1%) | 27% |
|
| EPS (5yr) | 36.9% | 16.0% | 87 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.4%) | (15.6%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 4 | |
| Current EPS | ($0.125) | ($0.474) | ($0.478) | |
| Month Ago EPS | ($0.120) | ($0.440) | ($0.435) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($0.122) | ($0.440) | ($0.443) | |
| Year/Year Chg | (0.8%) | 39.0% | 0.6% | |
| Financials | TSHA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($150) | ($43) | 9% |
|
| EPS (TTM) | ($0.414) | ($1.400) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($132) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $140 | $2 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $56 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $1,688 | $160 | 47% |
|
| Valuation | TSHA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.13 | 2.77 | 78% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TSHA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (37.2%) | (47.3%) | 15% |
|
| ROE | (47.1%) | (55.0%) | 16% |
|
| Liabilities to Assets | 17.7% | 29.6% | 11% |
|
| F-Score | 3 | 2 | 18% |
|
Taysha Gene Therapies, Inc. did not pass any screens on 8/20/2026.
